Stockwinners Market Radar for January 03, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EST Cathie Wood's ARK Investment bought 288K shares of SomaLogic today

20:07 EST Cathie Wood's ARK Investment bought 176K shares of Tesla today

18:42 EST Alphabet exec sells $1.99M in common stock - In a regulatory filing, Alphabet disclosed that its SVP Prabhakar Raghavan sold 22.2K shares of common stock on January 3rd in a total transaction size of $1.99M.

18:21 EST Bandera Capital's Greg Bylinsky buys 101K shares in Joint Corp. - In a regulatory filing, Bandera Capital's Greg Bylinsky disclosed 101K share purchase of Joint Corp on December 29th in a total transaction size of $1.38M. Shares of Joint Corp are up 4.6% afterhours at $14.40.

17:57 EST Lantern Pharma treatment of Mantle Cell Lymphoma granted orphan designation - Lantern Pharma's treatment of Mantle Cell Lymphoma was granted orphan designation by the FDA, according to a post to the agency's website. Reference Link

17:54 EST Planet Labs announces successful launch of 36 SuperDove satellites - Planet Labs successfully launched 36 SuperDove satellites, its Flock 4y, to space aboard a SpaceX Falcon 9 rocket. The Planet team has established contact with all 36 SuperDoves and has kicked off their automated commissioning process. This marks the company's 32nd successful launch, totaling over 500 satellites launched since its founding. These satellites were lofted into orbit from Space Launch Complex 40 in Cape Canaveral, Florida on SpaceX's Transporter-6 mission, marking Planet's eighth flight with the launch provider. Once in orbit, contact with the 36 SuperDoves was established, holding the company's 100% successful contact rate with its satellites. These 36 SuperDoves will replenish Planet's current fleet of approximately 200 satellites in orbit, working to scan the Earth every day to make change visible, accessible, and actionable. This data is incorporated into the workflows of over 800 customers globally and thousands of users in agriculture, sustainability, government, and more, to help power better decision making. From measuring crop yields to fighting illegal deforestation to supporting land restoration efforts, global users are finding great value in Planet's monitoring capabilities. The company is excited to bring even more SuperDove satellites to orbit to further its mission of making daily change visible, accessible, and actionable.

17:35 EST Osisko Development announces 'positive' feasibility study results for Cariboo - Osisko Development Corp. announced the results of an independent Feasibility Study prepared by BBA Engineering Ltd. in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects for the company's 100%-owned Cariboo Gold Project, located in central British Columbia. The FS outlines a robust and scalable phased development base case with low initial capital intensity of $137.3 million and attractive operating costs for the underground development of the Cariboo Gold Project, producing approximately 1.87 million ounces of gold over a 12-year mine life. Initial production in the first three years contemplates a 1,500 tonne per day operation from the Lowhee, Shaft and Mosquito deposits, yielding average annual production of 72,501 ounces. Concurrently, underground development will advance to ramp up operations to 4,900 tpd in year four, increasing average annual production to 193,798 ounces in Phase 2, with potential to scale production further in the future. Underground mining will be conducted using highly-mechanized, low-cost bulk tonnage methods designed to target the extraction of ore contained in gold vein corridors: a high-density network of mineralized quartz veins hosted mainly within unmineralized sandstone. A pre-concentration ore sorting facility is expected to significantly improve processed grades by separating non-mineralized material from ore, while substantially reducing processing volumes, energy costs, and the overall environmental impact footprint of the operation with fewer tailings, reduced water usage and ability to use waste as backfill. The Company remains on track for completing the Environmental Assessment process early in the second quarter of 2023 and anticipates receiving final permits by the end of 2023.

17:24 EST Morningstar chairman sell $2.09M in common stock - In a regulatory filing, Morningstar disclosed that its chairman Joseph Mansueto sold 9.6K shares of common stock on December 29th in a total transaction size of $2.09M.

17:20 EST Great Elm spikes almost 100% to $3.99 p/s after sale of medical equipment unit - Shares of Great Elm Group (GEG) spiked almost 100% to $3.99 in after-hours trading on Tuesday after announcing the sale of its durable medical equipment business for $80M. The company said Tuesday that it closed on the sale of its majority interest in Great Elm Healthcare to Quipt Home Medical (QUIP). "The successful sale of our DME business and the recently announced Forest transaction are transformative for Great Elm. When combined, the two transactions are expected to increase holding company cash by over $70 million. This allows Great Elm to dedicate more resources to scaling its Investment Management business, utilizing the expertise and relationships of our board and management team," said Jason Reese, Executive Chairman of GEG. "We continue to evaluate various strategies which could include investments in our existing funds or the acquisition of the management rights of new, long-duration capital vehicles. Additionally, the sale simplifies our reporting and organizational structure."

17:08 EST Pegasystems announces 4% workforce reduction, sees Q4 charge of $18.9M - In a regulatory filing, the company said, "Aligned with our target organization go-to-market strategy and commitment to be a Rule of 40 managed company, on January 3, 2023, Pegasystems announced a reduction in its workforce of approximately 4% of its employees across various geographies. Communications to impacted persons or their representatives are expected to be completed in the first quarter 2023. The company expects to incur a charge of $18.9 million in the fourth quarter of 2022 related principally to cash severance and related benefit costs for terminated employees."

17:01 EST Hawaiian Electric names Paul Ito as new CFO - Hawaiian Electric Industries, the parent company to Hawaiian Electric Compan and American Savings Bank, has appointed Paul K. Ito as executive vice president and CFO, effective January 1, 2023. Ito has been serving as HEI's interim CFO since July 2022.

16:59 EST NGL Energy Partners names Brad Cooper CFO - NGL Energy Partners announced that Brad Cooper will be promoted to Executive Vice President and Chief Financial Officer effective January 13, 2023. Cooper joined the Partnership in June 2021 as the Partnership's Senior Vice President of Administration and Risk Management. Cooper has over 20 years of experience in the energy space working for public companies with experience across upstream, midstream and downstream sectors. Most recently prior to joining the Partnership, Cooper spent 10 years with WPX Energy where he was Vice President of Finance and Treasurer. Prior to WPX Energy, he was at The Williams Companies where he held various corporate finance and risk management leadership roles.

16:56 EST SGH spikes almost 9% after reporting Q1 results that beat expectations - Shares of SGH are up 8.47% or $1.28 per share to $16.40 per share in after-hours trading after reporting Q1 results that beat on the top and bottom lines. "We are pleased with our financial results for the first quarter of fiscal 2023, highlighted by record non-GAAP gross margins of 27.8%, reflecting our focus on higher quality revenue, combined with the hard work of our dedicated employees," commented CEO Mark Adams. "Looking ahead, we expect to continue to strategically invest in our business while managing our operations in a prudent manner as we navigate a challenging economic environment," concluded Adams. SMART Global Holdings Sees Q2revenue $410M-$460M, consensus is 432.22M.

16:41 EST Phathom Pharmaceuticals down 25% after FDA notice of no action on vonoprazan NDA - Shares of Phathom Pharmaceuticals are down 25% or $2.99 afterhours at $9.00 after the company disclosed FDA notice that no action will be taken on the company's NDA for vonoprazan on or prior to the current PDUFA target action date of January 11, 2023.

16:37 EST Vera Therapeutics shares fall 67% despite ORIGIN trial meeting primary endpoint

16:34 EST Essential Utilities to sell West Virginia gas utility assets to Hope Gas - Essential Utilities "agreed to sell its West Virginia natural gas utility assets to Hope Gas, headquartered in Morgantown, WV. This move will allow the company to focus on - and prioritize - the growth of its utilities in states where it has scale, following its long-term strategy of infrastructure investment and growth by acquisition of water and wastewater systems. The remaining gas operations will continue to focus on capital improvements, operating excellence, and safety. The Peoples operation in Western Pennsylvania also will continue to play an important role in Essential's acquisition strategy as Aqua expands its footprint into the region, leveraging Peoples' valued brand and community relationships. Totaling approximately 13,000, the customer base of Peoples West Virginia is the smallest among all of the states where Essential operates. However, over the past two-and-a-half years, under the management of Essential and the dedicated WV employees, the company continued to make investments and operational improvements."

16:31 EST Vera Therapeutics announces ORIGIN clinical trial met primary endpoint - Vera Therapeutics announced the Phase 2b ORIGIN clinical trial of atacicept in patients with immunoglobulin A nephropathy, or IgAN, met its primary endpoint. Atacicept is the company's potential disease-modifying dual inhibitor of the cytokines B lymphocyte stimulator, or BLyS, and a proliferation-inducing ligand, or APRIL. ORIGIN is a multinational, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of atacicept in patients with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression despite available ACE or ARB therapy. The primary endpoint analysis, change in proteinuria as evaluated by urine protein creatinine ratio, or UPCR, at week 24 of the pooled 75/150 mg dose groups, achieved statistical significance and showed a 31% mean reduction versus baseline. Statistical significance was also achieved in the individual 150 mg dose group with a 33% mean reduction in proteinuria versus baseline and the all-atacicept group versus placebo, as shown in Figure 1. Safety results indicated that atacicept was generally well-tolerated and were consistent with the previously observed safety profile of atacicept, including a 1% discontinuation rate due to adverse events, or AEs, and comparable rates of infection compared to placebo. Serious treatment-emergent AEs were observed in 2% of patients in all atacicept arms and in 9% of patients in the placebo arm. These results build upon the prior integrated analysis of atacicept in randomized, double-blind, placebo-controlled clinical trials in over 1,500 patients to date - in which atacicept was well-tolerated. As a result of these positive data, Vera plans to advance atacicept into pivotal Phase 3 development in the first half of 2023, subject to and following discussions with the U.S. Food and Drug Administration. The full data sets from the ORIGIN clinical trial will be presented at a future medical meeting.

16:30 EST Phathom Pharmaceuticals trading resumes

16:26 EST Palomar announces completion of certain California earthquake programs - Palomar announced the successful completion of certain reinsurance programs covering California earthquake risk. The company renewed its California Commercial Earthquake quota share program, increasing the cession percentage, and secured additional earthquake excess of loss limit. In total, Palomar has secured approximately $50M of incremental limit to capitalize on opportunities it sees in the residential and commercial earthquake insurance markets.

16:17 EST Alamo Group increases regular dividend 4c to 22c per share - Alamo Group has declared its quarterly dividend of 22c per share, approving an increase from 18c per share to 22c per share. Payment will be made on February 1 to shareholders of record at the close of business on January 18.

16:15 EST Progress Software to acquire MarkLogic, terms undisclosed - Progress announced it has entered into a definitive agreement to acquire MarkLogic, a Vector Capital portfolio company. Upon closing of the planned transaction, MarkLogic is expected to enhance Progress' commitment of delivering the best products to develop, deploy and manage high-impact applications by providing a unified enterprise-grade semantic data platform that empowers customers to derive value from complex data. The company said, "MarkLogic offers a best-in-class, proprietary, multi-model NoSQL database, along with robust semantic metadata management and AI capabilities, complementing the larger Progress product portfolio. MarkLogic also aligns with Progress' Total Growth Strategy, adhering to Progress' disciplined acquisition criteria, offering scale, a strong recurring revenue model and products with high customer retention. The acquisition is also expected to provide an opportunity for Progress to leverage its highly disciplined operating model and infrastructure to maximize efficiency. When closed, the acquisition is expected to add more than $100 million in annual revenue and contribute strong cash flows, ultimately creating significant value for Progress shareholders."

16:12 EST Histogen announces Alfred Spada Ph.D asChief Scientific Officer - Histogen announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer. "We are very excited about Dr. Spada joining our management team. Dr. Spada is a world expert in both the biology of apoptosis and the chemistry of designing potent caspase inhibitors," said Steven J. Mento Ph.D., Executive Chairman and Interim President and Chief Executive Officer. "He is an excellent fit for Histogen's new direction which is focused on the development of our caspase inhibitors as innovative treatments for infectious and inflammatory diseases. His hiring is particularly timely as we move forward with our planning for the clinical trial of emricasan as a treatment for bacterial skin infections."

16:09 EST BioMarin's application for Voxzogo in achondroplasia validated by EMA - BioMarin announced that the European Medicines Agency - EMA - validated its Type II Variation application to extend the indication for Voxzogo for injection to treat children with achondroplasia under the age of 2. Validation confirms the submission is complete and begins the EMA's review process. The company also submitted a supplemental New Drug Application to the FDA to treat children with achondroplasia under the age of 5. Approval of the submissions would mean Voxzogo could potentially be prescribed as early as birth with more than 1,000 additional children eligible for treatment for achondroplasia, the most common form of disproportionate short stature in humans. The company anticipates action by health authorities in the second half of 2023. The supplemental marketing applications are based on the outcomes from a Phase 2 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of Voxzogo for injection in infants and children aged 3 months to less than five years old.

16:07 EST Public Storage CFO Tom Boyle to also serve as Chief Investment Officer - Public Storage "announced that Tom Boyle, the company's CFO, has been appointed to also serve as its Chief Investment Officer, effective January 1, 2023. In addition to his role as Chief Financial Officer, Mr. Boyle's responsibilities as Chief Investment Officer will include development, redevelopment, acquisitions, asset management, and third-party management."

16:05 EST L3Harris Technologies completes acquisition of Link 16 - L3Harris Technologies (LHX) "announced closing its acquisition of Viasat (VSAT) Tactical Data Links product line - commonly known as Link 16 - for approximately $1.96 billion, subject to customary adjustments. The company announced the signing of a definitive agreement to acquire the TDL network in October 2022 and secured U.S. and allied partner regulatory approvals in December."

16:04 EST Wag! Group to acquire Dog Food Advisor assets Clicks and Traffic LLC for $9M - Wag! Group "entered into a definitive asset purchase agreement with Clicks and Traffic LLC to purchase its Dog Food Advisor assets for cash consideration of $9 million. The transaction, which remains subject to customary closing conditions, is expected to close during the first quarter of 2023."

16:02 EST Allscripts changes corporate name to Veradigm - The company states: "Allscripts Healthcare announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. Allscripts had been transitioning its solutions to the Veradigm brand during 2022, and Allscripts will now formally be known as Veradigm. After more than two years of streamlining its corporate portfolio, all remaining Allscripts assets including electronic health records, practice management systems, and patient communication platforms are now integrated into the Veradigm Network, providing the connectivity needed to realize the vision of improved patient outcomes achieved more economically."

16:00 EST Phathom Pharmaceuticals trading halted, news pending

15:09 EST Amarin in patent infringement settlement with Health Net, no terms - According to a regulatory filing, out earlier on Tuesday, Amarin entered into a Settlement Agreement on December 26 with Health Net that resolves previously disclosed patent infringement litigation in the U.S. District Court in Delaware. The specific terms of the settlement are confidential. The Company is pleased with the outcome and believes entering into the Settlement Agreement will provide significant value in the market with payors. The Company will continue to vigorously defend its intellectual property rights related to VASCEPA.

14:25 EST Quipt Home Medical Corp trading halted, news pending

13:23 EST Valens obtains final court order approvng plan of arrangement with SNDL - The Valens Company (VLNS) announced that the Ontario Superior Court of Justice has granted a final order approving the previously announced plan of arrangement with SNDL (SNDL) under Section 192 of the Canada Business Corporations Act in accordance with the terms of the arrangement agreement between Valens and SNDL dated August 22, 2022. Under the terms of the Arrangement, Valens' shareholders will receive, for each common share of Valens, 0.3334 of a common share of SNDL. Based on the closing price of the SNDL shares on the Nasdaq Capital Market as at August 19, 2022, the consideration represents an implied value of $1.26 per Valens Share, for total consideration of approximately $138M. Completion of the Arrangement remains subject to certain other customary closing conditions as further described in the Arrangement Agreement, and, subject to the satisfaction or waiver of such closing conditions, the Arrangement is expected to be completed during January 2023.

13:16 EST Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 - Kiora Pharmaceuticals announced enrollment has been completed in its clinical study evaluating KIO-201 in patients with Persistent Corneal Epithelial Defects, or "PCED," a rare ocular condition characterized by non-healing wounds on the surface of the eye. Results from the study are expected to be reported at an upcoming medical conference in the first half of 2023. "This study is an important step to tackle some of the most challenging and difficult-to-treat corneal wounds. Current standard of care for these patients is sub-optimal with respect to outcomes and remains a substantial burden for patients. We believe KIO-201, an eye drop that is easily administered at home, addresses many of these challenges. As part of our development strategy of addressing unmet and orphan ophthalmic diseases, we have applied for Orphan Drug Designation of KIO-201 for PCED. Further, based on initial observations, we have started planning discussions with the FDA for a Phase 3 registration study of KIO-201 in PCED," said Eric Daniels, M.D., Chief Development Officer of Kiora Pharmaceuticals. Reference Link

13:03 EST Alvarium, Tiedemann complete business combination with Cartesian Growth - Tiedemann Group, Alvarium Investments and Cartesian Growth (GLBL) announced that they have completed their previously announced business combination. The Business Combination was approved at an extraordinary general meeting of stockholders of Cartesian on November 17, 2022, and closed today, January 3, 2023. The combined company now operates as Alvarium Tiedemann Holdings and its Class A common shares and warrants will begin trading on NASDAQ under the ticker symbols "ALTI" and "ALTIW," respectively, starting tomorrow, January 4, 2023.

12:30 EST Ryan Specialty Group completes acquisition of Griffin Underwriting Services - Ryan Specialty announced that it completed the acquisition of certain assets of Griffin Underwriting Services, a binding authority specialist and wholesale insurance broker headquartered in Bellevue, WA.

12:02 EST Teledyne acquires ChartWorld International, terms not disclosed - Teledyne Technologies announced that it has acquired ChartWorld International Limited and affiliates. ChartWorld, headquartered in Cyprus, with additional locations in Hamburg, Singapore, Vancouver and Tokyo, is provider of digital marine navigation hardware and software provided through an affordable subscription-based model. Terms of the transactions were not disclosed.Commercial maritime subscribers to ChartWorld's software as a service receive free type-approved Electronic Chart Display and Information Systems, a lifetime warranty and global 24/7 support. ChartWorld also provides digital Electronic Navigational Charts and other geospatial software and services, including digital route appraisal and voyage planning, as well as onshore software for fleet monitoring and risk assessment.

12:00 EST Lanvin Group falls -12.3% - Lanvin Group is down -12.3%, or -$1.12 to $8.00.

12:00 EST ProShares UltraShort Bloomberg Natural Gas rises 14.3% - ProShares UltraShort Bloomberg Natural Gas is up 14.3%, or $3.93 to $31.49.

12:00 EST Gaotu Techedu rises 29.2% - Gaotu Techedu is up 29.2%, or 69c to $3.05.

11:43 EST Foxconn, Nvidia partner to build automated electric vehicles - NVIDIA (NVDA) and Hon Hai Technology Group (HNHPF) announced a strategic partnership to develop automated and autonomous vehicle platforms. As part of the agreement, Foxconn will be a tier-one manufacturer, producing electronic control units based on NVIDIA DRIVE Orin for the global automotive market. Foxconn manufactured electric vehicles will feature DRIVE Orin ECUs and DRIVE Hyperion sensors for highly automated driving capabilities.

11:32 EST Thomson Reuters completes acquisition of SurePrep - Thomson Reuters closed on its previously announced acquisition of SurePrep, a US-based leader in 1040 tax automation software and services. On November 11, 2022, Thomson Reuters announced that it had reached a definitive agreement to acquire SurePrep for $500M in cash. The acquisition supports Thomson Reuters' strategy of pursuing both organic and inorganic growth opportunities as it promotes seamless, cloud-based workflows for professionals through innovative digital solutions and open, smart, and connected platforms. SurePrep will become part of Tax and Accounting Professionals operations, with revenues in both Tax & Accounting Professionals and Corporates. Thomson Reuters welcomes David Wyle and SurePrep colleagues to the team, ensuring continuity for customers, partners and employees as they continue to offer SurePrep as a market solution. As previously disclosed in the November 11, 2022 news release, SurePrep is expected to generate approximately $60less than of revenue in 2022 and grow in excess of 20% annually in the next few years. Adjusted EBITDA is expected to be neutral in the first year, followed by annual increases thereafter, as integration costs subside and revenue scales. Acquired deferred revenue is expected to be a modest free cash flow drag in the first year.

10:53 EST NuZee trading halted, volatility trading pause

10:09 EST Checkpoint Therapeutics trading resumes

10:00 EST Waterdrop falls -9.6% - Waterdrop is down -9.6%, or -32c to $3.01.

10:00 EST Valens Semiconductor falls -11.5% - Valens Semiconductor is down -11.5%, or -62c to $4.75.

10:00 EST ProShares UltraShort Bloomberg Natural Gas rises 13.5% - ProShares UltraShort Bloomberg Natural Gas is up 13.5%, or $3.71 to $31.27.

09:59 EST Checkpoint Therapeutics trading halted, volatility trading pause

09:47 EST Petrobras falls -7.7% - Petrobras is down -7.7%, or -82c to $9.82.

09:47 EST Korea Electric Power falls -10.6% - Korea Electric Power is down -10.6%, or -92c to $7.72.

09:47 EST Enfusion rises 10.4% - Enfusion is up 10.4%, or $1.01 to $10.68.

09:40 EST Gorilla Technology Group Inc trading resumes

09:35 EST Gorilla Technology Group Inc trading halted, volatility trading pause

09:34 EST ReShape Lifesciences Inc trading halted, volatility trading pause

09:30 EST Wildpack Beverage completes amalgamation with subsidiary - Wildpack Beverage announced the completion of its vertical short form amalgamation with its wholly owned subsidiary, Wildpack Beverage Alberta Inc. The Amalgamation, which became effective on January 1, 2023, brings together the two companies under a single entity, Wildpack Beverage Inc. The Amalgamation allows Wildpack to streamline its operations and better serve its customers by consolidating the Company's corporate structure and reducing costs.

09:30 EST indie Semiconductor announces strategic partnership with Seeing Machines - indie Semiconductor has announced a strategic partnership with Seeing Machines, computer vision technology company, to complement development of advanced vision processors for driver and vehicle occupant monitoring. Leveraging indie's global sales channels underpinned by leading tier 1 and vehicle OEMs, this partnership enables indie to deploy Seeing Machines' hardware-optimized, industry-leading Occula Neural Processing Unit technology into the Company's first generation of innovative vision sensing system-on-chips.

09:30 EST Burning Rock receives FDA Breakthrough Device Designation for OverC Test - Burning Rock announced that its OverC Multi-Cancer Detection Blood Test has been granted Breakthrough Device Designation by the US Food and Drug Administration, which is the third of its kind globally.

09:27 EST Terreno Realty sells industrial property in New Jersey for $24.3M - Terreno Realty sold an industrial property located in Bayonne, New Jersey on December 27, 2022 for a sale price of approximately $24.3M. The property consists of one industrial distribution building containing approximately 98,000 square feet on 3.6 acres which is 100% leased to one tenant. The property was purchased by Terreno Realty Corporation on March 31, 2014 for approximately $9.2M. The unleveraged internal rate of return generated by the investment was 14.1%.

09:27 EST Burning Rock Biotech's cancer detection test designated Breakthrough Device - Burning Rock's OverC Multi-Cancer Detection Blood Test has been granted Breakthrough Device Designation by the FDA, which is the third of its kind globally. OverC MCDBT is intended for early detection of multiple cancer types - esophageal, liver, lung, ovarian, and pancreatic cancers - in adults of either sex, aged 50-75 years old, at average risk for cancer. OverC MCDBT demonstrated a 69.1% of sensitivity and 98.9% of specificity in the case-control study, THUNDER, and will be further validated in prospective interventional studies among asymptomatic population. Compared with conventional cancer screening methods, liquid biopsy has the potential to increase detection efficiency and enable early diagnosis and treatment, thus improving patients' survival and quality of life while reducing social burden of the disease. In May 2022, Burning Rock received CE mark for its OverC MCDBT manufactured in both the US and China facilities. The FDA Breakthrough Device Designation granted for OverC MCDBT would pave the way for a clearer registration path through confirmative performance validation and utility establishment.

09:17 EST Lumentum names Caroline Pan as Chief Marketing Officer - Lumentum announced the appointment of Caroline Pan as Senior Vice President and Chief Marketing Officer, reporting to Alan Lowe, President and CEO. Pan will be responsible for leading Strategic Marketing, Corporate Marketing and Communications, and Lumentum Ventures, a company-wide initiative to drive market expansion through breakthrough innovation. Pan is a seasoned industry executive with nearly 30 years of experience across the high-tech, industrial, and automotive sectors. Before joining Lumentum, she was the Chief Marketing Officer for Bright Machines, a venture-backed software and robotics company that provides intelligent automation solutions for discrete manufacturing.

09:16 EST EzFill adds 10 fleet accounts in December - EzFill Holdings announced it added 10 new fleet accounts during the month of December, bringing to approximately 100 the number of fleet accounts added in 2022.The new fleet accounts include companies ranging from moving and storage to transportation, auto dealerships, building supply, professional cleaning services, furniture delivery and a nationally recognized consumer product manufacturer. The new accounts added in December will have regularly scheduled fuel deliveries for more than 180 customer vehicle assets and are expected to result in over 460,000 additional gallons of fuel delivered annually.

09:14 EST Aurinia Pharmaceuticals enters patent settlement pact with Sun Pharmaceutical - Aurinia Pharmaceuticals announced it has entered into a settlement agreement with Sun Pharmaceutical Industries, Sun Pharmaceuticals Industries and Sun Pharma Global FZE that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review, or IPR, directed at Aurinia's U.S. Patent No. 10,286,036, as well as settlement of the ongoing patent infringement litigation in the United States related to Sun's Cequa product. Under the settlement agreement, which is contingent upon the U.S. Patent Trial and Appeal Board approving the joint motion to terminate the IPR, both parties agreed to dismiss their claims and counterclaims against each other and cease bringing any future further action against the other.

09:10 EST Immersion announces 10c special cash dividend and new $50M stock buyback - Immersion reported management changes, a special cash dividend and a new stock repurchase program. Effective immediately, Executive Chairman Eric Singer has been appointed President and CEO and will continue to serve as Chairman of the Board. Immersion's Board of Directors has also declared a special one-time dividend of 10c per share, based on the Company's strong operating performance in 2022. This dividend is in addition to a new recently declared quarterly dividend program of 3 cents per share. In addition, Immersion's Board of Directors approved a new stock repurchase program of up to $50M for 2023. This new stock repurchase program replaces the stock repurchase program that had been in place in 2022 under which the Company repurchased a total of 2,542,065 shares .

09:09 EST Navidea receives notice of allowance from USPTO - Navidea announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled, "Compositions And Methods For Altering Macrophage Phenotype (US Application #16/832,620)." Broadly, this patent covers the ability of Navidea's constructs to stimulate the body's immune response against tumors through targeted delivery of payloads that change the nature of macrophages to make them more proinflammatory. These constructs have demonstrated the ability to rally an immune response against tumors and make other therapies work more effectively against those tumors in preclinical studies. If confirmed in clinical trials, the ability to increase the efficacy of cancer therapeutics by harnessing the body's immune system could bring significant benefits to patients. The Notice of Allowance concludes the substantive examination of the patent application and is expected to result in the issuance of a U.S. patent after administrative processes are completed. When issued, this patent will protect key elements of Navidea's cancer immunotherapy product pipeline. Navidea's cancer immunotherapy product pipeline consists of a series of mannosylated-amine dextrans that carry small molecule drug payloads that are attached to MADs by degradable linkers. The MADs bind to CD206 receptors on tumor associated macrophages and related cells such as dendritic cells and myeloid derived suppressor cells. The degradable linkers are designed to release their small molecule payloads inside the CD206 expressing cells. The small molecule payloads are designed to induce proinflammatory behaviors in these cells.

09:08 EST Finacity facilitates renewal of $550M securitization for Hapag-Lloyd - Finacity Corporation announces that they have renewed and extended an existing receivables securitization for another 3 years with Hapag-Lloyd, a company headquartered in Hamburg, Germany. The facility is collateralized by Hapag-Lloyd's global freight receivables. Finacity serves as the ongoing Administrator, providing analytic, reporting and structuring support, as well as the Back-up Servicer for the multi-bank facility.

09:07 EST Singing Machine, Stingray announce automotive karaoke system - The Singing Machine Company (MICS) announced its latest partnership with leading music, media and technology company Stingray (STGYF) to launch the world's first fully-integrated hardware and software in-car karaoke solution for the global automotive market. The new launch represents a key step forward in Singing Machine's expansion into new high-growth business-to-business verticals. Singing Machine will be launching a commercially available in-car karaoke microphone, specially designed to fully integrate with global car manufacturers and Stingray's proprietary karaoke automotive app. The in-car karaoke system will have safety features and proprietary technology that allows for vocal enhancements. "We're thrilled to be working with our longtime strategic partner, Stingray, to create the world's first in-vehicle karaoke solution for the global market," said Gary Atkinson, CEO of Singing Machine. "This launch represents a key shift in our product strategy, offering auto manufacturers a chance to integrate a new immersive karaoke experience within their product lineup."

09:06 EST Canacol Energy says gas sales averaged 177 MMscfpd in December - Canacol Energy provides the following information concerning its December 2022 natural gas sales. December Gas Sales of 177 MMscfpd: Realized contractual natural gas sales were 177 million standard cubic feet per day for December 2022, representing low interruptible gas sales due to very high rainfall levels during the month.

09:04 EST Donald Trump Jr. launches 'Triggered with Don Jr.' on Rumble - Rumble announced that Donald Trump Jr. will launch his new show, "Triggered With Don Jr.," the week of January 23rd exclusively on Rumble. The businessman, author and political commentator brings his brand to "Triggered With Don Jr.," which will be released twice a week. The show will stream live exclusively on Rumble and will be available on Locals, Rumble's subscription platform, where following each episode, Don Jr. will take live questions from viewers.

09:04 EST UC Investments to invest $4B in Blackstone Real Estate Income Trust - The Office of the Chief Investment Officer of the Regents of the University of California, or "UC Investments," and Blackstone announced a long-term strategic venture in which UC Investments will invest $4 billion in Blackstone Real Estate Income Trust, or "BREIT," Class I common shares, the largest existing share class. Blackstone will then contribute $1 billion of its current BREIT holdings as part of a strategic venture with UC Investments. Stephen Schwarzman, Chairman, CEO and Co-Founder of Blackstone, said, "Blackstone is committed to bringing the highest quality alternative investment products to individual investors to improve their returns. UC Investments' $4 billion investment is validation of this strategy, and we are proud to add the UC system to the more than 200,000 investors already benefitting from BREIT. UC Investments' commitment builds upon its 15-year partnership with Blackstone and gives BREIT increased balance sheet flexibility and capital during an opportune deployment period for all our investors."

09:02 EST LPL Financial: Matt Irwin joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor Matt Irwin has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reported having served approximately $160 million in advisory, brokerage and retirement plan assets, and joins LPL from Ameriprise.

08:50 EST Macau reports December casino revenue down 56.3% to 3.48B patacas - Macau's gaming bureau reported December gross revenue from games of fortune in the region was down 56.3% year-over-year to 3.482B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link

08:44 EST American Acquisition target Royalty Management expands investment in Ferrox - American Acquisition Opportunity's merger target company, Royalty Management Corporation has expanded its stake in one of its portfolio holdings, Ferrox Holdings through a common stock issuance; issuing stock in Royalty Management Corporation for approximately 10% of Ferrox. The common stock issued by Royalty Management Corporation for its investment in Ferrox is valued at $10.00 per share equivalent of American Acquisition Opportunity's stock post the pending merger.

08:43 EST American Resources' ReElement produces lithium from recycled batteries - American Resources Corporation announced that it has achieved ultra-high pure lithium from its exclusively licensed and patented multi-modal chromatography technology that was developed in partnership with Purdue University. ReElement is focused on selling its high-purity lithium carbonate to the domestic battery manufacturing industry to help satisfy the need for domestically supplied battery materials and aligns with the clean vehicle tax credit as part of the Inflation Reduction Act. With its initial commercial battery production train at its first Noblesville, Indiana facility, ReElement has the capacity to process approximately 137,500 kilograms per year of battery materials to produce ultra-high pure battery minerals or compounds. The Company is in the design and engineering phase to implement its second battery production line which will have an annual capacity of approximately 13,750,000 kilograms per year with the ability to efficiently expand on a modular basis thereafter. As previously announced, this is in addition to its initial commercial production train that is used to recycle end-of-life permanent magnets for the separation and purification of their inherent rare earth elements. The Company continues to scale its first rare earth and critical element recycling facility in Noblesville, Indiana which is being developed as a modularly-scalable, commercial facility and is also currently evaluating additional sites for both standalone and co-located facilities.

08:41 EST Expion360 selected by Imperial Outdoors as lithium-ion battery supplier - Expion360 has been selected as the exclusive supplier of high-energy lithium-ion batteries for a new off-grid, extreme overland RV camper series manufactured by Imperial Outdoors. The win for Expion360 builds upon a multi-year supplier relationship with the manufacturer. Expion360 has already begun shipping lithium batteries to Imperial Outdoors for installation, with the extreme overland RV campers available today for purchase through Imperial Outdoors dealerships nationwide.

08:39 EST Nocturne Acquisition, Cognos Therapeutics enter business combination agreement - Nocturne Acquisition Corporation announced execution of a definitive business combination agreement with Cognos Therapeutics, a medical technology company focused on developing unique, radically advanced devices delivering drugs for the treatment of neurological diseases including brain and spinal cancers, neurodegenerative disorders, epilepsy, and stroke. The all-stock deal contemplates that Cognos' stockholders will receive, in the aggregate, $120 million of Nocturne common stock, with each such Nocturne common share valued for the transaction at $10.30. Certain outstanding options and warrants to acquire capital stock of Cognos would be assumed by Nocturne. The SINNAIS Implantable Smart Pump is Cognos' next-generation drug delivery system designed to deliver drugs to just the targeted tissue, bypassing the blood-brain barrier, or to other tissues with minimal off-target side effects. This capability is intended to make the modern, potent drugs developed by the pharmaceutical industry more effective with high concentrations at the targeted tissue and decreased concentrations systemically. Cognos is also in the process of preliminary development of a skull-mounted optical sensor, an implantable shunt that enables the collection of clinically significant parameters from the disease target site and transmits such data to a cloud base infrastructure for analysis to further customize drug dose to patient disease progression and permit near real-time monitoring. Cognos' management believes that this innovation will bridge the virtual divide between physician and patient, bringing personalized medicine and the virtual physician concept to reality. Cognos has initiated plans to enter both the U.S. and EU markets following regulatory approval. Initial discussion has been held with the U.S. Food and Drug Administration regarding the future Premarket Approval Application for SINNAIS indicated for infusion of Infumorph into cerebral spinal fluid. This PMA would potentially utilize the Six-Year Rule under which a PMA application may leverage clinical data in an existing approval and new clinical data does not need to be developed. Going forward, the company also intends to develop and seek FDA approvals of the SINNAIS pump for novel metronomic delivery approaches for other drug products in other clinical indications, including an intended initial indication of leptomeningeal carcinomatosis. These FDA approvals will likely require clinical studies. The plan in the EU is to obtain CE certification for a general claim for drug delivery. The transaction has been unanimously approved by the respective boards of directors of Cognos and Nocturne and is subject to approval by stockholders of Nocturne and Cognos and other customary closing conditions. The proposed business combination is expected to be completed in the second or third quarter of 2023.

08:37 EST Zai Lab appoinst Amado as President, Head of Global Oncology R&D - Zai Lab (ZLAB) announced the appointment of Rafael Amado, M.D. as President, Head of Global Oncology Research and Development, R&D, effective December 30, 2022. Dr. Amado will report to Dr. Du and will be a key member of the Company's executive committee. He will be responsible for leading and overseeing the Company's global oncology research and development activities. Dr. Amado joins Zai Lab from Allogene Therapeutics (ALLO), where he has served as Executive Vice President, Head of Research and Development and Chief Medical Officer since September 2019.

08:36 EST Standard BioTools appoints Jensen as Chief Human Resources Officer - Standard BioTools (LAB) announced the appointment of Betsy Jensen as Chief Human Resources Officer. Jensen will lead Standard BioTools human resources function and will report to President and Chief Executive Officer Michael Egholm, PhD. Jensen was most recently Chief Human Resources Officer at Gibraltar (ROCK) a position she held since March 2021.

08:35 EST Monterey Capital Acquisition Corp trading resumes

08:33 EST Streamline Health signs new contract with health system based in Tennessee - Streamline Health Solutions announced it has signed a contract with an 850-bed, Epic-EHR health system based in Tennessee. The organization will use eValuator's automated pre-bill coding analysis technology to help improve revenue integrity and financial performance. "We are pleased to partner with another large health system to help ensure revenue integrity prior to billing," stated Ben Stilwill, President, Streamline Health. "We look forward to supporting this client through our mission to ensure our healthcare providers are paid accurately for the care they provide."

08:32 EST 9F Inc to implement ADS ratio change - 9F Inc. will change the ratio of its ADSs to its Class A ordinary shares, par value $0.00001 per share, from the current ratio of one ADS to one Class A ordinary share to a new ratio of one ADS to 20 Class A ordinary shares. For the company's ADS holders, the change in the ADS Ratio will have the same effect as a one-for-twenty reverse ADS split. The company anticipates that the change in the ADS Ratio will be effective on or about January 18 subject to the effectiveness of the post-effective amendment to the ADS Registration Statement on Form F-6 on or before that date. Holders of uncertificated ADSs in the Direct Registration System and in The Depository Trust Company will have their ADSs automatically exchanged and need not take any action. The company's ADSs will continue to be traded on the Nasdaq Global Market under the symbol "JFU." No fractional new ADSs will be issued in connection with the change in the ADS Ratio. The change in the ADS Ratio will have no impact on the company's underlying Class A ordinary shares, and no Class A ordinary shares will be issued or cancelled in connection with the change in the ADS Ratio.

08:23 EST Monterey Capital Acquisition, ConnectM enter merger agreement - Monterey Capital Acquisition Corporation (MCAC) and ConnectM Technology Solutions announced today the signing of a definitive merger agreement. Upon closing of the transaction, the newly combined company will operate under the name ConnectM Technology Solutions, Inc. and plans to list on Nasdaq under the symbol CNTM, subject to Nasdaq approval, stockholder approval and other customary closing conditions. The company said, "ConnectM has a current base of 22,000+ customers and 12 OEMs between its two platforms. Aurai is an integrated platform for electrification, decarbonization and energy efficiency and Yantra is ConnectM's EV, micro mobility, and fleet management platform. ConnectM employs a unique customer acquisition strategy blending all-digital marketing, white label OEM integration and acquisitions of complementary businesses with customer bases that present upsell opportunities. ConnectM was #772 in the INC 5000 list for 2021 - their annual ranking of the fast growing companies in America, #17 in Boston, and #20 in Energy overall." Under the terms of the transaction, MCAC has agreed to acquire ConnectM at an implied pre-money equity valuation of $145 million, subject to an upward adjustment depending on the extent to which MCAC's transaction expenses exceed $8.0 million. MCAC holds approximately $93.0 million of cash in its trust, subject to potential redemptions by MCAC's existing stockholders. As part of the Merger, the outstanding equity of ConnectM will be converted into equity of MCAC. The Merger has been approved unanimously by the boards of directions of both MCAC and ConnectM and is expected to close in the second quarter of 2023,subject to review and approval by the U.S. Securities and Exchange Commission of the registration statement on Form S-4 to be filed with the SEC, regulatory and stockholder approvals and other customary closing conditions. Certain stockholders of both MCAC and ConnectM have entered into agreements pursuant to which they have committed to vote their respective shares in favor of the Merger.

08:20 EST BIO-key appoints Rodgers as VP of Channels, Carter as VP North American Sales - BIO-key International announced the appointment of Galen Rodgers, Vice President, VP, of Channels, and Chad Carter, VP North America Sales. The appointments are effective today, January 3, and are in anticipation of the planned retirement of Chief Revenue Officer Fred Corsentino. Galen Rodgers, who will report to Chairman & CEO Michael DePasquale, brings 20+ years of experience. Most recently, Rodgers was Director of Channel Sales Americas for Ping Identity Corporation. Chad Carter, who will report to Mark Cochran, President of PortalGuard, has over 25 years of security and networking solutions experience. Recently, Carter served as VP of Sales for North America at Wallix.

08:17 EST Canadian National ratified new collective agreement with union - CN announced that on December 23, 2022, the Teamsters Canada Rail Conference ratified a new collective agreement. The agreement covers approximately 160 rail traffic controllers in Canada. "We are pleased to have negotiated a new collective agreement before the expiry of the previous one. We are committed to working with our railroaders and their union representatives to create a workplace where employees thrive and together, we deliver better and safer service to our valued customers," said Tracy Robinson, President and Chief Executive Officer, CN. The agreement came into effect on January 1, 2023 and includes adjustments to wages of 3% in 2023, 3% in 2024 and 2.5% in 2025 and other benefits. The agreement is in effect until December 31, 2025.

08:16 EST Weatherford appoints Mitra as executive vice president, CFO - Weatherford International (WFRD) has appointed Arun Mitra as the Company's Executive Vice President and Chief Financial Officer, CFO. Mitra's appointment is effective immediately. Before joining Weatherford, Mitra served as the Executive Vice President and Chief Financial Officer of Mitsubishi Power Americas (MSBHF).

08:15 EST Baker Hughes to supply technology for PETRONAS Carigali's offshore CCS project - Baker Hughes announced it has been awarded a contract to be booked in the fourth quarter of 2022 by Malaysia Marine and Heavy Engineering, MMHE, to supply carbon dioxide compression equipment to PETRONAS Carigali Sdn. Bhd.'s Kasawari offshore carbon capture and sequestration, CCS, project in Sarawak, Malaysia. The project is expected to be the world's largest offshore CCS facility, with capacity to reduce CO2 emissions by 3.3 million tons per annum, MTPA. Baker Hughes will deliver a compression solution with minimized footprint and weight, as well as a power density allowing for larger flows per unit and best-in-class efficiency. The CCS project is expected to significantly reduce CO2 volume currently emitted via flaring of the overall Kasawari gas development, supporting PETRONAS' ambitions to unlock Malaysia's potential to be a global carbon capture, utilization and storage, CCUS, hub and enable the company to progress towards achieving its own net zero carbon emission targets by 2050. "This award demonstrates the viability of significant, commercial-scale carbon-capture projects, which are critical for the energy transition," said Rod Christie, executive vice president of Industrial & Energy Technology at Baker Hughes. "This project proves that CCS technology can be deployed even in challenging environments, including offshore gas facilities, and provides an important step forward for reducing emissions from natural gas production." Baker Hughes will deliver two trains of low-pressure booster compressors to enable CO2 removal through membrane separation technology, as well as two trains for reinjecting the separated CO2 into a dedicated storage site. The trains, which will be fitted with PGT25+ and PGT25 gas turbines with Dry Low Emission technology, offer greater fuel efficiency and reduced nitrogen oxides emissions even with high CO2 content fuel gas. The compressors' casing also enables a reduced footprint compared to other standard solutions, a key differentiator in an offshore environment.

08:13 EST Researchers' reanalysis questions mortality data in FOURIER trial - In research published in BMJ, Juan Erviti, James Wright, Ken Bassett and others stated that they observed some inconsistencies between the information in the Clinical Study Report and that in the 2017 primary trial results publication for the FOURIER trial of evolocumab. In that context, they "aimed to restore the mortality data in the FOURIER trial based on the information contained in the death narratives in the CSR." The researchers conclude that after readjudication, "deaths of cardiac origin were numerically higher in the evolocumab group than in the placebo group in the FOURIER trial, suggesting possible cardiac harm." Reference Link

08:13 EST Sesen Bio holders Radoff and Torok back vote against Carisma transaction - Bradley L. Radoff and Michael Torok who own approximately 8.4% of the outstanding common stock of Sesen Bio, reiterated their intent to vote against the Company's proposed merger with Carisma Therapeutics through the following statement: "After reviewing the amended merger terms disclosed last week, the Investor Group remains firmly opposed to what we deem an illogical, value-destructive transaction. We contend that Sesen Bio's stockholders would be far better off if the merger was terminated and the Company's approximately $140M in cash was efficiently returned to investors along with the contemplated contingent value right instrument. We estimate the cash available to return to the Company's stockholders would translate to at least 70c per share - representing an approximately 15% premium to where the Company's stock currently trades against the backdrop of the flawed merger. The Company's stockholders could receive additional upside value from the CVR.

08:12 EST Ceridian National Trust Bank authorized to open by OCC - Ceridian announced that the Office of Comptroller of the Currency has authorized the Ceridian National Trust Bank to open on January 3, 2023. Effective on this day, the Ceridian National Trust Bank commenced banking operations, acting as trustee for Ceridian's U.S. payroll trust. Historically, certain aspects of Ceridian's U.S. client money movement activity have been subject to regulation at both the federal and individual state levels with resulting inherent complexity across multiple jurisdictions. With the establishment of the Ceridian National Trust Bank, regulatory oversight will now be under the OCC, a single federal government agency. Ceridian's payroll trust structure will continue to benefit Ceridian customers by providing bankruptcy-remoteness protection for client funds pending remittance to employees of our clients, tax authorities, and other payees.

08:09 EST Establishment Labs enters Mia Femtech agreement in Japan - Establishment Labs announced it has entered into an agreement with Seishin Plastic and Aesthetic Surgery Clinic in Japan for Mia Femtech. Seishin Plastic and Aesthetic Surgery Clinic was founded in 1993 and operates 10 premium plastic surgery clinics in Japan. Mia will be first available at Seishin's main Tokyo clinic in Roppongi and at their newest clinic in Ginza. Mia Femtech is Establishment Labs' breakthrough minimally invasive breast aesthetics experience. The patented technologies used with Mia can increase breast shape by 1 to 2 cups in a 15-minute procedure without the need for general anesthesia.

08:08 EST Bath & Body Works appoints Hollander as VP, Investor Relations - Bath & Body Works (BBWI) announced the appointment of Heather Hollander as Vice President, VP, Investor Relations, effective immediately. Hollander will be responsible for leading the company's investor relations program, including engagement with shareholders, investors and the analyst community. She will report to Wendy Arlin, Chief Financial Officer. Hollander most recently served as Head of Investor Relations at Nordstrom (JWN) from July 2021 to December 2022.

08:07 EST Daxor announces new published study using its BVA-100 blood test - Daxor Corporation announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor's BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary artery diastolic pressure, PADP, monitor - two key metrics of cardiovascular congestion. Pressures, as a proxy measure, are sometimes used in guiding volume management decisions by clinicians. Data from the study demonstrated a lack of correlation between pressure measures and actual blood volume, highlighting the need for direct and 98% accurate volume measurement that the BVA-100 blood test provides. The study titled, "Pressure-Volume Profiles in Heart Failure Across Sexes and Phenotypes," assessed the relationship between cardiac filling pressures and total blood volume measurement using Daxor's BVA-100 blood test between sexes and left ventricular ejection fraction, key clinical determinants of response to therapy and outcomes in heart failure. "More than 135 published peer-reviewed studies, and over a dozen this past year alone, have proven that blood volume analysis informs clinicians with critical information to manage and treat volume derangements in heart failure and many other medical conditions," said Michael Feldschuh, President, and CEO of Daxor Corporation. "This study adds further validation that surrogate markers are not accurate for volume management compared to direct and objective measurement with blood volume analysis. Mounting evidence continues to support substantial improvements in mortality reduction, hospital readmission and length of stay, and costs from the use of our highly accurate diagnostic."

08:06 EST Worksport to attend CES Las Vegas for strategic discussions, meetings - Worksport is announcing that a special Company Task Force will be visiting the Las Vegas Consumer Electronics Show January 5-7 and will hold strategic discussions about Worksport's innovative zero-emission alternative power products with key stakeholders, suppliers, and potential clients. Worksport, a manufacturer of tonneau covers for light trucks, has been developing two proprietary and advanced products for the automotive accessories market -- SOLIS, a solar-powered pickup truck cover that feeds power to its companion, and COR, a portable battery with advanced hot swap technology. The company's management group also intends to meet with the CES representatives to discuss Worksport and the possibility of exhibiting its unique power electronics and solar solutions at future shows.

08:06 EST Decarbonization Plus Acquisition IV, Hammerhead file proxy statement - Decarbonization Plus Acquisition Corporation IV announced that DCRD's definitive proxy statement relating to the previously announced business combination with Hammerhead Resources, an oil and natural gas exploration, development and production company, has been filed with the U.S. SEC on December 30, 2022. DCRD has commenced mailing of the Proxy Statement and a notice and voting instruction form or a proxy card relating to the extraordinary general meeting of DCRD shareholders to DCRD shareholders of record as of the close of business on December 14, 2022, who will be entitled to attend and participate in the Shareholders' Meeting.

08:05 EST MiMedx appoints Ricci Whitlow as COO - MiMedx Group (MDXG) announced that it has appointed Ricci Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company's manufacturing, supply chain, procurement, quality, and regulatory functions. Ms. Whitlow joins MIMEDX from Catalent (CTLT), where she most recently served as President, Clinical Supply Services.

08:04 EST Athenex's oral paclitaxel did not receive regulatory approval from U.K. MHRA - Athenex announced that its proprietary Oral Paclitaxel formulation did not receive regulatory approval from the United Kingdom's, U.K., Medicines and Healthcare Products Regulatory Agency, MHRA, for metastatic breast cancer based solely on CMC issues. The MHRA application was not rejected based on any clinical efficacy or safety concerns expressed by the MHRA. MHRA regulations allow an applicant to request a re-examination of an opinion by an independent board which the Company plans to pursue. The Company views the identified CMC issues as addressable. "While we are disappointed by the MHRA decision, we are encouraged that we have satisfactorily addressed any major concerns related to the clinical efficacy and safety of Oral Paclitaxel. We believe the iSPY 2 study is an important data set that further characterizes the safety profile of Oral Paclitaxel and we plan to amend our metastatic breast cancer NDA with the iSPY 2 safety data this quarter," said Dr. Johnson Lau, Chief Executive Officer of Athenex. "To maximize the value of Oral Paclitaxel, we expect to re-engage the FDA by amending our metastatic breast cancer NDA with the iSPY 2 data, and pursue opportunities to advance development of Oral Paclitaxel in the neoadjuvant breast cancer setting in light of recent graduation of Oral Paclitaxel from the iSPY 2 program."

08:04 EST C.H. Robinson CEO Bob Biesterfeld steps down, Scott Anderson named interim CEO - C.H. Robinson announced that Scott Anderson, chair of the board of directors has been appointed interim CEO, effective January 1, 2023. Bob Biesterfeld has stepped down as president and CEO and as a member of the board, effective December 31, 2022. The board has commenced a search for a new permanent CEO and has retained Russell Reynolds, an executive search firm, to assist in the process of identifying internal and external candidates. With Anderson's appointment as interim CEO, Jodee Kozlak will become independent chair of the C.H. Robinson board. C.H. Robinson has also made changes to the membership of the Audit Committee and Governance Committee so that these committees remain composed solely of independent directors, and appointed Kermit Crawford the Chair of the Governance Committee.

08:03 EST Ansys acquires particle dynamics simulation software Rocky - Ansys announced the acquisition of Engineering Simulation and Scientific Software Rocky DEM - Rocky -. With this acquisition, Ansys adds Rocky, the leading discrete element method - DEM - tool, and a team of developers, application support technicians and customer-facing staff in Brazil, Spain, and the U.S. The transaction is not expected to have a material impact on Ansys' consolidated financial statements in 2023. Rocky was a subsidiary of Engineering Simulation and Scientific Software, a Ansys Channel Partner, and developer of engineering software dedicated to modeling discrete mechanics problems. Rocky's software is used in a variety of cross-industry applications that involve discrete solids of any size and shape and simulates the dynamic flow behavior of discrete solids and particle-laden free-surface flows in multiple industries.

08:02 EST S&W Seed, Trigall Genetics to form joint venture in Australia - Trigall Genetics, co-owned by Bioceres Crop Solutions (BIOX) and Florimond Desprez, and S&W Seed Company (SANW), have entered into a joint venture to advance wheat breeding activities in Australia. Trigall Australia will develop and market high performing wheat varieties for the Australian market, leveraging S&W's existing commercial footprint and Florimond Desprez's and Bioceres Crop Solutions' breeding expertise. The program will encompass both conventional and transgenic varieties, including Bioceres Crop Solutions' drought-tolerance HB4(R) technology and EcoWheat(R) technologies, that can contribute to improving yields in a region whose productivity has been increasingly affected by drought and soil salinization. The new breeding program is expected to benefit from the introduction of top tier genetics from Florimond Desprez and Trigall Genetics worldwide breeding programs, combined with state-of-the-art facilities to accelerate genetic gain for the region.

08:00 EST Monterey Capital Acquisition Corp trading halted, news pending

07:37 EST Skeena Resources closes sale of royalty on Eskay Creek for C$27M - Skeena Resources (SKE) closed a royalty sale with Franco-Nevada Corporation (FNV) pursuant to which Skeena granted a 0.5% net smelter returns royalty on the Eskay Creek gold-silver Project to Franco-Nevada in exchange for a closing cash consideration of C$27M and contingent cash consideration of C$1.5M. As highlighted in the Company's September 26, 2022 news release, Skeena repurchased this 0.5% NSR from Barrick Gold Corporation (GOLD) after it was initially granted in connection with the acquisition of Eskay Creek. The Royalty Transaction was signed and closed concurrently on December 30, 2022. In connection with this transaction, Skeena terminated Franco-Nevada's right of first refusal to purchase a 0.5% NSR on Eskay Creek, which right was granted to Franco-Nevada on December 24, 2021. The net proceeds of the Royalty Transaction will be used by the Company to fund exploration and development activities at Eskay Creek and for general administration and corporate purposes.

07:34 EST Watsco board increases quarterly dividend to $2.45 per share - Watsco Board of Directors has declared a regular quarterly cash dividend of $2.45 on each outstanding share of its Common and Class B common stock payable on January 31, 2023 to shareholders of record at the close of business on January 17, 2023.

07:32 EST Evaxion receives approval from FDA to proceed with Phase 2b study for EVX-01 - Evaxion Biotec announced that the U.S. Food and Drug Administration, FDA, determined that the Company may proceed with its Phase 2b clinical trial of EVX-01. On December 22, 2022, the FDA issued approval for the Company to proceed with its Phase 2b trial. The Company anticipates a response to the Fast Track designation submission in the first quarter of 2023. "Receiving a green light from the FDA is a tremendous boost for our personalized cancer vaccine program. EVX-01 is already actively enrolling patients in Australia, and the FDA approval expands our ability to move forward quickly with our lead program in malignant melanoma. Moreover, the FDA is a universally recognized national authority, and its endorsement is an important step towards demonstrating a clinically meaningful benefit of our first personalized cancer vaccine," says Erik Heegaard, Chief Medical Officer at Evaxion. The Phase 2b study will be conducted at clinical sites across the United States, Europe, and Australia. It is carried out in collaboration with Merck, supplying its PD-1 inhibitor KEYTRUDA. The trial was first initiated in Australia with the enrollment of the first patient in September 2022.

07:22 EST Media and Games Invest says registered office relocated to Sweden - The Company now announces that its registered office and headquarters have been successfully relocated from Malta to Stockholm, Sweden. Remco Westermann, CEO of MGI said, "I am very happy that we have successfully relocated to Sweden and are now a full Swedish company as of today. Our link to Sweden started back in 2018, when we placed our first bond in Sweden. At that time still with revenues of EUR 45m and without offices and employees in Sweden. What followed was the dual listing of our shares on Nasdaq First North Premier in Stockholm at the end of 2020, as well as further successful fundraising activities and corporate actions. Today we have revenues of over EUR 300m and have several offices, many employees and even more supportive investors in Sweden and the Nordics. I am convinced that without our strategic focus on Sweden and the Nordics, our operational success would not have been possible in the way it has been in the past years. Also, Sweden's very high reputation and good governance standards played an important role in MGI's decision to select Sweden as it's domicile. We expect the relocation to be a further accelerator in this respect, opening the company to further investor groups and lowering the risk premium due to further improved governance. Many thanks to all partners, investors and shareholders who have accompanied and supported us for enabling this relocation."

07:21 EST Idaho Strategic provides 2022 review, 2023 objectives - Idaho Strategic Resources provides the following review of 2022 and objectives for 2023.Early in 2022 Idaho Strategic added Rich Beaven to its Board of Directors and completed its up listing onto the New York Stock Exchange American in March. In celebration of IDR's up listing, the company rang the opening bell of the NYSE from underground at the Golden Chest Mine, becoming the first company in history to do so. Following the up listing, Idaho Strategic's management participated in the "Idaho Mining, Critical Minerals, and Water Resources" panel discussion in Boise, ID, appeared as a guest on the Planet MicroCap Due Diligence Podcast, and attended the 18th Annual International Rare Earth Elements Conference. Throughout 2022 there were several announcements/executive orders/bills proposed to President Biden and the U.S. Government with the goal of showing support for domestic critical mineral production in order to reduce the U.S.' reliance on foreign sources. The most notable of which were the Inflation Reduction Act, the recent expansion of the Defense Production Act, the Thorium Energy Security Act, the 2023 Omnibus Appropriations Bill, and the Industrial Base Policy Consortium. While many of these have been aimed at the processing and permitting of domestic critical minerals, the shift toward domestic mining has begun. IDR continues to advance its Diamond Creek, Roberts, and Lemhi Pass rare earth elements projects and continued expanding its partnerships with local stakeholders like Idaho National Labs, the University of Idaho, and the Idaho Geological Survey to potentially appeal to larger Government programs. At the closing of 2022, IDR also announced a business combination proposal to Westwater Resources' Stakeholders. For a more comprehensive overview of IDR's offer, please read our press release dated Dec. 22nd, 2022. IDR's management continues to believe that the combination of the two companies represents an attractive opportunity for the stakeholders of both. While members of Westwater's management initially responded not in favor of the proposal, Idaho Strategic is a shareholder-focused company and believes that Westwater's shareholders deserve to have a voice with regard to the proposal. IDR's management has evaluated its next steps, beginning with a recent invitation to Westwater's management to engage in further discussion/negotiation. Since adding our Diamond Creek and Roberts rare earth elements projects in 2020, they have proven to be transformative additions for the Company and led to IDR's addition of Lemhi Pass in 2022, which is not only the largest known concentration of Thorium resources in U.S., but also a highly prospective rare earth element property as well. It became apparent to us during the year that the prior work and coverage conducted over the area has made 'Lemhi Pass' a more well-known location amongst industry folks and academics. In 2022 IDR completed its inaugural drill program at Diamond Creek despite the Moose Fire doing its best to delay the program by nearly 3 months. With the results from our drill program expected to be released early in 2023, IDR has taken a proactive approach by expanding its land position and partnerships within the industry. In addition to conducting one of the few REE drill programs in the country in 2022, Idaho Strategic is now the second largest rare earth elements landholder in the United States and has accumulated much of the land along the Idaho REE-Th Belt, which runs subparallel to the Idaho Cobalt Belt. Also in 2022, Idaho Strategic announced its partnership in the IGEM Program along with the University of Idaho, Idaho National Labs, the Center for Advanced Energy Studies, and the Idaho Geological Survey in a research program to discover environmentally friendly processes for the separation and extraction of rare earth elements using drill core and surface samples from IDR's Diamond Creek property. The IGEM program is currently underway and is being funded by the Idaho Department of Commerce. In order to support Idaho Strategic's investment in its rare earth projects, the Company purchased a building in Salmon, ID during 2022 in part due to the obvious cost savings over time and to establish a more permanent presence in the community. The property was nicely setup for core cutting, storage, and living and will serve as a great base of operations for future exploration and development work. Rounding out Idaho Strategic's busy 2022 are the achievements the Company has made at its Golden Chest Mine and the surrounding Murray Gold Belt district. The Company experienced a very high success rate drilling at the Golden Chest Mine in 2022 leading to the further delineation of two ore shoots, the Klondike and the Paymaster, which are adjacent to the Skookum shoot. In September of 2022, the Company drove an exploration drift from the currently producing Skookum shoot into the nearby Klondike shoot to follow-up and confirm vein orientations, sizes, and grades that were discovered with the drill. Once the exploration drift into the Klondike began, IDR shifted the focus of its drilling to the Paymaster shoot for the remainder of 2022. With consistent and favorable results coming from the Paymaster drill program, the Company has plans to begin to drive a similar style exploration drift into the Paymaster shoot during 2023. Because we have the necessary skillsets, it was presented to the team to determine if the Paymaster development under IDR's existing cost structure was feasible. This 'goal' included the completion of ample development ahead of production in the Skookum in order to begin development toward the Paymaster without the need to greatly increase the current level of manpower. In addition to the Company's favorable production-based drilling at the Golden Chest, Idaho Strategic conducted the first ever drill program on its additional 7,000 acres of contiguous patented and unpatented mining claims that surround the Golden Chest Mine within the Murray Gold Belt. On September 1st, 2022, IDR released favorable results from a drill hole in an area of land referred to as the Argus. The results from the Argus drill program help confirm IDR's belief that the Murray Gold Belt has district scale potential and remains as one of the last great undeveloped patented/private land holdings in the western U.S. Beyond drilling/exploration, Idaho Strategic has advanced its gold production and is currently mining the 821-level underground within the Skookum shoot. Throughout 2022 IDR began its transition from a mix of underground and open pit operations to solely producing from underground. In response to softening gold prices and higher inflation in the second half of 2022, IDR implemented a revised mine plan which prioritized the higher-grade stopes on the North side of the Skookum ore shoot which has worked out favorably so far. Also in 2022, Idaho Strategic completed a ~$600k expansion of its New Jersey Mill tailings storage facility located in Kellogg, ID, providing the company with greater flexibility and timing with regard to building a new mill on-site within the Murray Gold Belt.

07:16 EST Helius Medical launches UpScript telehealth e-commerce site - Helius Medical Technologies launched a new e-commerce site that makes it easier for Americans experiencing issues with their gait to obtain the company's innovative Portable Neuromodulation Stimulator. When combined with an exercise regimen supervised by a physical therapist, the PoNS device improves gait impairment in people with MS. This is the first time that Helius, a neurotech company focused on neurological wellness, has made PoNS available online via telehealth. The UpScript Platform makes it possible for people with MS to have a PoNS device delivered directly to their doorstep - a potential game-changer for someone facing walking challenges. Accessed via ponstherapy.com, the site is powered through a new partnership with UpScript, a leading telehealth company focused on making medications and devices available direct-to-consumer. UpScript's platform provides for online health evaluations with qualified medical providers, fulfillment of prescriptions required for PoNS Therapy and shipping of PoNS devices directly to the homes of eligible patients in the United States.

07:14 EST PolyPid announces publication of Phase 2 clinical trial analysis of D-PLEX100 - PolyPid announced the peer-reviewed publication of a post-hoc analysis from the previously-completed Phase 2 study of D-PLEX100 for the prevention of surgical site infections, SSIs, in abdominal surgery. The paper, entitled, "Reduction in Surgical Site Infections by Localized Administration with D-PLEX100 in Patients with Multiple Risk Factors Undergoing Colorectal Surgery," was published in the American Journal of Surgery and can be found here. The Phase 2 trial was a prospective, multicenter, randomized, controlled, single-blind, two arm study and was designed to assess the efficacy and the safety of D-PLEX100 in addition to standard of care in preventing superficial and deep SSIs in patients undergoing elective colorectal surgery. Thirty-day SSI rates were examined in patients in the Intention-to-treat population and in those with two or more patient related risk factors. The distribution of the assessed risk factors between the D-PLEX100 plus SoC and SoC cohorts was approximately even. Two hundred and one patients were evaluated in the ITT population, 101 in the intervention arm and 100 in the control arm. The study showed a 53% statistically significant relative risk reduction of the SSI rate within 30 days post-index surgery in the D-PLEX100 cohort compared to SoC. In patients with two or more risk factors, the SSI rate in the D-PLEX100 plus SOC cohort was 15.8% compared to 37.5% in the SOC alone cohort, demonstrating a statistically significant relative risk reduction of 58%.

07:13 EST Steakholder Foods receives grant of up to $1M for 3D structured fish products - Steakholder Foods has received its first grant to develop 3D-printed structured eel and grouper products with Singaporean cultivated fish and seafood company Umami Meats. The initiative is being funded by a grant from the Singapore Israel Industrial R&D Foundation, a cooperation between Enterprise Singapore and the Israel Innovation Authority. Steakholder Foods' partnership with Umami Meats offers an opportunity for market entry in the only country in the world where cultivated meat has regulatory approval. The collaboration aims to develop a scalable process for producing structured cultivated fish products. Steakholder Foods will use its newly developed technology for mimicking the flaky texture of cooked fish that was recently submitted for a provisional patent application. The project's first prototype, a structured hybrid grouper product, is expected to be completed by Q1. The product will be printed using Steakholder Foods' proprietary 3D bio-printing technology and bio-inks that will be customized for Umami Meats' cells.

07:12 EST Lucira Health submits EUA for OTC use of its COVID-19 & Flu test - Lucira Health announced that it submitted an Emergency Use Authorization, EUA, application to the FDA for over-the-counter, OTC, use of its simple, at-home molecular COVID-19 & Flu test. Lucira's test for COVID-19 & Flu was granted Emergency Use Authorization for Point-of-Care use in a healthcare setting in November 2022. In seeking OTC authorization, Lucira intends to make the test broadly available to consumers both online as well as in pharmacies. Lucira worked closely with the FDA to complete additional testing to demonstrate that the COVID & Flu test could be used by consumers at home

07:11 EST Bitfarms mines 496 new bitcoin in December - Bitfarms provided a Bitcoin, BTC, production and mining operations update for December 2022. "In December, we energized the remaining portions of The Bunker and Garlock farms, executing our Canadian expansion plan two and one-half months ahead of schedule," said Geoff Morphy, CEO of Bitfarms. "Activating the full 96-megawatts in Sherbrooke, as well as completing Warehouse One in Rio Cuarto, and renegotiating miner contract commitments, we have positioned ourselves for strategic growth with minimal cash outlay in 2023." Select Operating Highlights: 4.5 EH/s online as of December 31, 2022, up 105% from December 2021 and up 2% compared to November 30, 2022. 4.38 EH/s average online for the month of December. 113 BTC/average EH/s for the month of December, up 8% from 105 in November 2022. 496 new BTC mined during December 2022, up 37% from December 2021 and up 9% from November 2022. 16 BTC mined daily on average in December, equivalent to about US$265,600 per day and approximately US$8.2 million for the month based on a BTC price of US$16,600 on December 31, 2022.

07:10 EST Piedmont Lithium jumps 9% to $47.99 after amended pact with Tesla

07:09 EST Chemomab Therapeutics' CM-101 meets endpoints in Phase 2a liver fibrosis trial - Chemomab Therapeutics reported top-line results from its Phase 2a trial assessing CM-101, its first-in-class CCL24-neutralizing monoclonal antibody, in non-alcoholic steatohepatitis - NASH - patients. The trial met its primary endpoint of safety and tolerability, and CM-101 achieved reductions in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments measured at baseline and at week 20. This trial was primarily designed to assess the subcutaneous formulation of CM-101 and to evaluate the drug's impact on liver fibrosis biomarkers relevant to both NASH and the rare fibro-inflammatory conditions that represent the focus for the company, such as primary sclerosing cholangitis and systemic sclerosis. CM-101 continues to appear safe and was well tolerated when administered subcutaneously. CM-101 administered subcutaneously demonstrated favorable pharmacokinetics and target engagement profiles as expected; they were similar to what the company has previously reported. CM-101-treated patients showed greater improvements than the placebo group in a number of liver fibrosis-related biomarkers. A higher proportion of patients in the CM-101-treated group showed improvement in a physiologic measure of liver stiffness as compared to placebo. After completion of the study, the unblinded data showed that patients in the CM-101-treated group had higher baseline levels of fibrosis compared to placebo-treated patients. The impact of this difference on the results, if any, is unknown.

07:07 EST Aslan, Thermo Fisher announce partnership for manufacturing eblasakimab - ASLAN Pharmaceuticals (ASLN) and Thermo Fisher Scientific (TMO) announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials. ASLAN has developed a high concentration formulation of eblasakimab, allowing up to 400mg eblasakimab to be administered in a single subcutaneous injection and suitable for use with different devices. Thermo Fisher plans to commence manufacturing the new formulation in its commercial-scale Good Manufacturing Practices, GMP, certified manufacturing facilities in January 2023. "Establishing this partnership with Thermo Fisher, a global leader in biologics manufacturing, is an important strategic milestone as we continue to advance the development of eblasakimab towards global Phase 3 clinical trials. Thermo Fisher has made deep investments in biologics development and offers 20 years of process development experience in over 240 biologics development programs, as well as a global infrastructure to scale up biologics manufacturing and deliver production continuity," said Kiran Asarpota, Chief Operating Officer, ASLAN Pharmaceuticals. "We are confident we have identified the best partner to deliver high-quality drug substance with our new formulation, a critical activity we have been planning for to be Phase 3 ready soon after the readout from the TREK-AD study, with no impact on our previously reported cash runway."

07:06 EST Centene's Health Net selected for new medi-cal direct contracts - Centene announced the California Department of Health Care Services has selected its California subsidiary Health Net of California for direct contracts in Los Angeles and Sacramento counties, increasing the number of direct county contracts by DHCS to 10. The new contracts are anticipated to begin January 1, 2024. In total, Health Net will provide Medi-Cal managed care services in Los Angeles, Sacramento, Amador, Calaveras, Inyo, Mono, San Joaquin, Stanislaus, Tulare and Tuolumne counties. Health Net did not receive an award in San Diego. Health Net continues to serve members in Fresno, Imperial, Kings, and Madera counties via other contractual arrangements. Health Net will end its legal actions related to the RFP. Based upon the anticipated structure of California as described above, as well as the potential slight impact of Defense Health Agency's recent TriCare announcement, the company is lifting its projected 2024 adjusted EPS floor to $7.15 from $7.00.

07:06 EST Carrols Restaurant appoints Hoffman as Chief Restaurant Officer - Carrols Restaurant announced the appointment of Joseph Hoffman as Chief Restaurant Officer, a new executive level position created to oversee Carrols' restaurant operations, effective January 1, 2023. In his new role, which was approved by the Board on December 20, 2022, Hoffman will report directly to Interim President and CEO Anthony Hull. Hoffman served as Senior Vice President, Operations of Carrols from May 2022 to December 31, 2022, as a Division Vice President, Operations from June 2017 until April 2022, and as a Vice President, Region Director from June 1997 until May 2017. Hoffman has been an employee of Carrols since 1993, when he joined the Company as a District Manager.

07:05 EST NRx Pharmaceuticals announces dosing in NRX-101 trial - NRx Pharmaceuticals announced that its first clinical trial site has been contracted and that first dosing of patients is expected in early 2023. This Phase 3 clinical trial of NRX-101 is for the treatment of Severe Bipolar Depression with Acute Suicidal Ideation and Behavior, or SBD-ASIB, a lethal condition that currently takes the lives of thousands of Americans each year. NRX-101 is the first investigational medicine to target this condition, for which the only currently approved treatment is Electroconvulsive Therapy.

07:04 EST RedHill Biopharma's RHB-204 shows positive Phase 2 results in COVID-19 - RedHill Biopharma announced publication of positive data from a Phase 2 study of once-daily oral investigational RHB-107 in non-hospitalized symptomatic COVID-19 patients, in the peer-reviewed International Journal of Infectious Diseases. The study showed that RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the small number of patients in each treatment group, including faster recovery from severe COVID-19 symptoms and 100% reduction in hospitalization due to COVID-19. Data showed a 100% reduction in hospitalization due to COVID-19, with 0/41 patients on the RHB-107 arms versus 3/20 hospitalized on the placebo-controlled arm. The study also showed an approx. 88% reduction in reported new severe COVID-19 symptoms after treatment initiation, with only 2.4%, 1/41, of the RHB-107 treated group versus 20%, 4/20, of patients in the placebo-controlled arm reporting new severe COVID-19 symptoms. Further analysis showed faster recovery from severe COVID-19 symptoms with a median of 3 days to recovery with upamostat vs. 8 days with placebo. Advanced discussions are ongoing regarding inclusion of once-daily oral RHB-107 in a multinational platform trial for COVID-19 outpatients. Discussions for external non-dilutive funding for Phase 3 COVID-19 development, in addition to the platform study, are also advancing.

07:03 EST Innoviz Technologies selected by LOXO for autonomous vehicles - Innoviz Technologies announced that Switzerland-based LOXO, a provider of zero-emission autonomous vehicles for last-mile delivery services, is planning to use InnovizOne LiDAR to enable autonomy for its delivery vehicles, which allow retailers to transport goods from local distribution hubs to end consumers more efficiently and with fewer emissions. Innoviz's planned partnership with LOXO for autonomous delivery services in Switzerland demonstrates the company's continued global expansion. Following the initial evaluation period, LOXO plans to purchase more InnovizOne LiDAR units to support its delivery fleet, with pre-sales for the vehicle beginning as soon as 2023.

07:02 EST Great Elm sells majority interest in Forest Investments to JPMorgan affiliate - Great Elm (GEG) announced its sale of a majority of its ownership interest in Forest Investments to J.P. Morgan Broker-Dealer Holdings (JPM). Transaction Highlights: GEG has sold 61% of its direct and indirect common equity of Forest to JPM for approximately $18M in cash. Together with its purchase of 20% of the common equity of Forest in December 2020, JPM owns 81% of Forest as of December 30, 2022. GEG has the right to put its remaining 19% ownership interest in Forest for cash proceeds of approximately $27M. Jason Reese, Executive Chairman of GEG, said, "The Forest transaction represents a successful outcome for Great Elm's shareholders. This marks the latest in a series of strategic actions taken to enhance our focus and capabilities across our core investment management strategy. We are pleased to have worked with JPM as a financial partner in Forest. This transaction underscores the ability for Great Elm to raise capital as it looks to grow its investment management business."

06:56 EST Asensus Surgical: Kitakyushu General Hospital to initiate second Senhance System - Asensus Surgical announced that Kitakyushu General Hospital, a hospital in the Kyushu area of Japan, entered into an agreement to lease and utilize a second Senhance Surgical System, at the end of December 2022. Kitakyushu is the first hospital to install multiple Senhance Surgical Systems. The hospital previously initiated their first Senhance system in January of 2020, and since has completed over 300 procedures utilizing Performance-Guided Surgery.

06:50 EST Stewart announces promotions in its legal department - Stewart announced that effective January 1, Elizabeth Giddens has assumed the role of Chief Legal Officer & Corporate Secretary, after the planned retirement of John Killea as Chief Legal Officer and Chief Compliance Officer. Mary Thomas has been promoted to Chief Compliance and Regulatory Officer. Thomas has spent her entire 16-year career at Stewart. Pamela O'Brien has been named General Counsel of Stewart Title Guaranty Company. Giddens's succession of Killea was announced in October as she was hired as Deputy Chief Legal Officer to work alongside Killea during his transition. Giddens comes to Stewart with 25 years of legal experience, including five years at an international law firm and 16 years at several public companies, most recently serving as Senior VP and General Counsel at Integer Holdings, where she led its legal department.

06:47 EST Stellex Capital affiliate acquires G2, LCI, and Fintellix from TransUnion - An affiliate of Stellex Capital Management has acquired G2 Web Services, Lundquist Consulting, and Fintellix India Private Limited from TransUnion. The Platform is comprised of leading and tenured businesses, focusing on deploying sophisticated data-driven solutions to provide mission-critical risk, fraud mitigation, and regulatory compliance services to their respective global clients within the financial and digital commerce sectors. An affiliate of Stellex will be investing in the Platform's people, technology, and products with the goal of continuing to enhance its value proposition to customers. In conjunction with the transaction, Stellex named Brian Longe as CEO of the newly formed Platform. Mr. Longe brings over 30 years of experience growing technology and data services businesses in both private equity backed and public markets settings. Most recently, he served as the CEO of Sontiq, a top-rated identity theft protection provider to businesses and consumers. Prior to Sontiq, Longe served as the CEO of Wolters Kluwer Financial Services and American Stock Transfer & Trust Company. The transaction closed on December 30, 2022. DLA Piper acted as legal counsel to Stellex.

06:39 EST Molina Healthcare to double California revenue with Medi-Cal contracts in 2024 - Molina Healthcare confirmed that the California Department of Health Care Services has announced the awards of Medi-Cal contracts to Molina Healthcare of California commencing on January 1, 2024. The December 30th announcement confirms Molina's footprint including Medi-Cal awards in each of Riverside, Sacramento, San Bernardino, and San Diego Counties and as a subcontractor in Los Angeles County. Under the finalized award, Molina's Medi-Cal membership is expected to grow from approximately 600,000 members as of September 30, 2022, to approximately 1.2 million members in 2024. Molina's current annual premium revenue related to its Medi-Cal contract of approximately $1.9B is now expected to be approximately $3.9B for full year 2024 versus the prior expectation of $5.5B based on DHCS's August 2022 announcement. The projected combined 2024 revenues of California, Nebraska, and Iowa now total $4.2B. Incremental earnings from these recently announced portfolio additions are updated to at least $3.50 per share at full run rate, now reflecting portfolio target margins and modest operating leverage.

06:35 EST InterDigital renews two patent licenses with Panasonic - InterDigital (IDCC) announced that the company has renewed two patent licenses with Panasonic Entertainment & Communication Co. (PCRFY). "We are delighted to continue our longstanding business relationship with Panasonic," commented Eeva Hakoranta, Chief Licensing Officer, InterDigital. "These licenses, which cover our DTV and HEVC patents, were signed under our HEVC program, and under our joint digital TV licensing program which continues to deliver considerable value to InterDigital, our partner Sony, and to our licensees."

06:32 EST InterDigital and Samsung to renew license agreement - InterDigital (IDCC) has agreed to renew its patent license agreement with Samsung (SSNLF) Electronics. The parties will enter into binding arbitration to determine the final terms, including the amount payable by Samsung under the new agreement. Samsung's previous license to InterDigital's portfolio of cellular wireless and video technologies expired on December 31st 2022. The new license will be effective from January 1st 2023.

06:06 EST KBR announces VAM technology for grassroots production facility in India - KBR announced that its proprietary Vinyl Acetate Monomer, or VAM, technology has been selected by Asian Paints Limited for a grassroots production facility in India. Under the terms of the contract, KBR will provide technology licensing, basic engineering, proprietary equipment, and catalyst for a 100,000 tons per annum VAM facility. KBR's VAM technology is offered in alliance with Showa Denko K.K., based in Japan.

06:03 EST Ouster to supply digital lidar sensors to Cyngn autonomous driving platform - Ouster (OUST) has signed a strategic customer agreement with Cyngn (CYN). The agreement will add Ouster's new REV7 digital lidar sensors to the Cyngn DriveMod platform that delivers autonomous solutions for both existing and new material handling vehicles in 2023. Ouster will showcase Cyngn's DriveMod platform, outfit with a REV7 sensor, on a Columbia Stockchaser cargo vehicle at CES 2023 in the Las Vegas Convention Center from January 5-8. Together, Ouster and Cyngn aim to provide autonomous solutions to address significant challenges common to many industrial organizations such as labor shortages, costly safety incidents, and increased consumer demand for e-commerce requiring more automation. DriveMod is an all-in-one autonomy integration package that enables the conversion of standard industrial vehicles into fully autonomous ones by utilizing advanced lidar sensors, hardware components, and AI software. DriveMod can be installed into new vehicles off the assembly line or retrofitted into existing vehicles.

05:36 EST So-Young increases share repurchase program to $25M - So-Young announced that its board of directors has authorized an adjustment to the company's previously adopted share repurchase program, increasing the aggregate value of shares that the company is authorized to repurchase under the program from $15M to $25M. The share repurchase program is effective for a 12-month period beginning from November 18.

05:19 EST Hutchmed completes patient enrollment for ESLIM-01 trial - Hutchmed announced that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia, or ITP, in China. The last patient was enrolled on December 31.

05:07 EST Root says former employee transferred payments without disclosure - Root disclosed late Friday that its Audit, Risk and Finance Committee of the board of directors has engaged outside counsel to conduct an internal investigation with respect to a series of marketing services transactions that a former senior marketing employee entered into in 2022. This internal investigation is ongoing, but the preliminary results indicate that, with respect to one vendor, these transactions involve payments from the company of at least $9.5M, which the company now believes was subsequently transferred at such former employee's direction and without prior disclosure to company senior management, from that vendor to entities in which the former employee had an interest. Root expects to write off the full $9.1M that had been recognized as prepaid expense within other assets in our condensed consolidated balance sheet as of September 30, 2022. The "investigation continues and may result in the discovery of further fraudulent and/or inappropriate transactions, including transactions that may have caused the Company to make payments for marketing services that were not provided or not fully provided and are not expected to be fully provided," Root added. The company said it will pursue recovery of these funds "through all legally available means and cooperate with law enforcement as appropriate." Root has voluntarily notified the Department of Justice and Securities and Exchange Commission, as well as certain state regulators, and intends to cooperate fully with these agencies.

04:40 EST Univar confirms Brenntag talks ended, weighing other interest - Univar Solutions (UNVR) confirmed that Brenntag (BNTGY) has ended its discussions with the company about a potential transaction. Univar said it is "committed to acting in the best interest of its stockholders and will continue discussions relating to other indications of interest that have been received with respect to a potential transaction."